银屑病关节炎不同类别靶向治疗相关严重感染风险:基于法国医疗保险数据库(SNDS)的全国队列研究
该全国队列研究纳入2015年1月1日至2021年6月30日新使用靶向治疗的成人银屑病关节炎患者12071例,采用倾向评分加权Cox模型比较严重感染风险。共识别367例严重感染(粗发生率17.0/1000人年,95%CI 15.2至18.7)。与阿达木单抗新使用者相比,依那西普(wHR 0.72;95%CI 0.53至0.97)和乌司奴单抗(wHR 0.57;95%CI 0.35至0.93)新使用者的严重感染风险显著较低,其他靶向治疗未见统计学显著改变。
要点
- 银屑病关节炎靶向治疗新使用者中严重感染粗发生率为17.0/1000人年(95%CI 15.2至18.7)。
- 与阿达木单抗相比,依那西普严重感染风险显著较低(wHR 0.72;95%CI 0.53至0.97)。
- 与阿达木单抗相比,乌司奴单抗严重感染风险显著较低(wHR 0.57;95%CI 0.35至0.93)。
核心结论
- 在真实世界环境中,银屑病关节炎靶向治疗新使用者的严重感染发生率较低。
- 相对于阿达木单抗新使用者,依那西普和乌司奴单抗新使用者的严重感染风险较低,其他药物未见统计学显著改变。
研究设计与样本
- 法国全国队列研究,使用法国医疗保险计划行政医疗数据库链接医院出院数据库,纳入2015年1月1日至2021年6月30日新使用靶向治疗的成人银屑病关节炎患者。
- 共纳入12071例患者(平均年龄48.7±12.7岁;6965例(57.7%)为女性),采用倾向评分加权Cox模型进行时间至事件分析,以阿达木单抗为对照,估计加权HR(wHR)及95%CI。
主要发现
- 共识别367例严重感染(占患者3.0%),粗发生率为17.0/1000人年(95%CI 15.2至18.7)。
- 经逆倾向评分加权并调整时变协变量和日历年之后,依那西普新使用者严重感染风险显著低于阿达木单抗新使用者(wHR 0.72;95%CI 0.53至0.97)。
- 乌司奴单抗新使用者严重感染风险显著低于阿达木单抗新使用者(wHR 0.57;95%CI 0.35至0.93)。
- 其他靶向治疗与阿达木单抗相比,严重感染风险未见统计学显著改变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the risk of serious infection associated with different targeted therapies for psoriatic arthritis (PsA) in real-world settings. METHODS: This nationwide cohort study used the administrative healthcare database of the French health insurance scheme linked to the hospital discharge database to identify all adults with PsA who were new users of targeted therapies (adalimumab, etanercept, golimumab, certolizumab pegol, infliximab, secukinumab, ixekizumab, ustekinumab, and tofacitinib) from 1 January 2015 to 30 June 2021. The primary outcome was a serious infection (ie, requiring hospitalisation), in a time-to-event analysis using propensity score-weighted Cox models, with adalimumab as the comparator, estimating weighted HRs (wHRs) and their 95% CIs. RESULTS: A total of 12 071 patients were included (mean age 48.7±12.7 years; 6965 (57.7%) women). We identified 367 serious infections (3.0% of patients), with a crude incidence rate of 17.0 per 1000 person-years (95% CI, 15.2 to 18.7). After inverse propensity score weighting and adjustment for time-dependent covariates and calendar year, risk of serious infection was significantly lower for new users of etanercept (wHR 0.72; 95% CI, 0.53 to 0.97) or ustekinumab (wHR, 0.57; 95% CI, 0.35 to 0.93) than adalimumab new users. This risk was not statistically modified with the other targeted therapies. CONCLUSIONS: The incidence of serious infection was low for PsA patients who were new users of targeted therapies in real-world settings. Relative to adalimumab new users, this risk was lower among new users of etanercept and ustekinumab and unmodified for the other molecules.
引用
- Bastard L, Claudepierre P, Penso L, et al. Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS). RMD Open. 2024. PMID: 38485454. doi:10.1136/rmdopen-2023-003865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。